Krsnaa Diagnostics Limited Logo

Krsnaa Diagnostics Limited

KRSNAA.NS

(2.2)
Stock Price

925,40 INR

5.14% ROA

7.85% ROE

44.42x PER

Market Cap.

26.705.248.489,00 INR

15.24% DER

0.3% Yield

9.74% NPM

Krsnaa Diagnostics Limited Stock Analysis

Krsnaa Diagnostics Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Krsnaa Diagnostics Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (19.04%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

5 Dividend Growth

The company's dividend growth has been consistently strong over the past three years, with annual increases that demonstrate its commitment to rewarding shareholders.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (633) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 ROA

The stock's ROA (0%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Krsnaa Diagnostics Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Krsnaa Diagnostics Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Krsnaa Diagnostics Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Krsnaa Diagnostics Limited Revenue
Year Revenue Growth
2016 568.895.596
2017 1.075.700.000 47.11%
2018 2.092.350.000 48.59%
2019 2.584.270.000 19.04%
2020 3.964.560.000 34.82%
2021 4.554.500.000 12.95%
2022 4.871.230.000 6.5%
2023 6.217.960.000 21.66%
2023 4.871.230.000 -27.65%
2024 6.809.280.000 28.46%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Krsnaa Diagnostics Limited Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Krsnaa Diagnostics Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 124.970.513
2017 175.050.000 28.61%
2018 52.340.000 -234.45%
2019 65.780.000 20.43%
2020 107.880.000 39.02%
2021 64.420.000 -67.46%
2022 81.490.000 20.95%
2023 0 0%
2023 654.680.000 100%
2024 493.640.000 -32.62%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Krsnaa Diagnostics Limited EBITDA
Year EBITDA Growth
2016 144.810.171
2017 321.920.000 55.02%
2018 593.830.000 45.79%
2019 742.970.000 20.07%
2020 1.055.400.000 29.6%
2021 1.450.080.000 27.22%
2022 1.416.800.000 -2.35%
2023 1.437.840.000 1.46%
2023 1.442.460.000 0.32%
2024 1.706.720.000 15.48%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Krsnaa Diagnostics Limited Gross Profit
Year Gross Profit Growth
2016 420.161.970
2017 311.060.000 -35.07%
2018 1.918.990.000 83.79%
2019 2.307.040.000 16.82%
2020 3.127.090.000 26.22%
2021 3.951.540.000 20.86%
2022 4.129.440.000 4.31%
2023 3.970.840.000 -3.99%
2023 3.317.370.000 -19.7%
2024 2.417.840.000 -37.2%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Krsnaa Diagnostics Limited Net Profit
Year Net Profit Growth
2016 -39.246.951
2017 -601.570.000 93.48%
2018 -580.570.000 -3.62%
2019 -1.119.510.000 48.14%
2020 1.849.290.000 160.54%
2021 683.880.000 -170.41%
2022 621.110.000 -10.11%
2023 419.840.000 -47.94%
2023 568.370.000 26.13%
2024 716.840.000 20.71%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Krsnaa Diagnostics Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 -4
2017 -58 94.83%
2018 -18 -222.22%
2019 -36 48.57%
2020 59 160.34%
2021 23 -163.64%
2022 20 -15.79%
2023 13 -46.15%
2023 20 31.58%
2024 22 13.64%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Krsnaa Diagnostics Limited Free Cashflow
Year Free Cashflow Growth
2016 90.099.122
2017 -578.600.000 115.57%
2018 -415.110.000 -39.38%
2019 -389.400.000 -6.6%
2020 357.180.000 209.02%
2021 -37.950.000 1041.19%
2022 -650.590.000 94.17%
2023 -1.715.660.000 62.08%
2023 0 0%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Krsnaa Diagnostics Limited Operating Cashflow
Year Operating Cashflow Growth
2016 621.985.593
2017 327.850.000 -89.72%
2018 582.660.000 43.73%
2019 378.090.000 -54.11%
2020 1.025.580.000 63.13%
2021 1.284.240.000 20.14%
2022 763.010.000 -68.31%
2023 223.210.000 -241.84%
2023 0 0%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Krsnaa Diagnostics Limited Capital Expenditure
Year Capital Expenditure Growth
2016 531.886.471
2017 906.450.000 41.32%
2018 997.770.000 9.15%
2019 767.490.000 -30%
2020 668.400.000 -14.82%
2021 1.322.190.000 49.45%
2022 1.413.600.000 6.47%
2023 1.938.870.000 27.09%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Krsnaa Diagnostics Limited Equity
Year Equity Growth
2016 757.059.344
2017 -228.960.000 430.65%
2018 -849.210.000 73.04%
2019 -1.969.770.000 56.89%
2020 2.318.650.000 184.95%
2021 6.687.100.000 65.33%
2022 7.387.360.000 9.48%
2023 8.098.020.000 8.78%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Krsnaa Diagnostics Limited Assets
Year Assets Growth
2016 1.756.251.657
2017 2.943.040.000 40.33%
2018 5.289.850.000 44.36%
2019 6.299.820.000 16.03%
2020 6.045.300.000 -4.21%
2021 8.761.530.000 31%
2022 9.098.930.000 3.71%
2023 11.719.130.000 22.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Krsnaa Diagnostics Limited Liabilities
Year Liabilities Growth
2016 999.192.313
2017 3.172.000.000 68.5%
2018 6.139.060.000 48.33%
2019 8.269.590.000 25.76%
2020 3.726.650.000 -121.9%
2021 2.074.430.000 -79.65%
2022 1.711.570.000 -21.2%
2023 3.621.110.000 52.73%

Krsnaa Diagnostics Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
191.15
Net Income per Share
18.62
Price to Earning Ratio
44.42x
Price To Sales Ratio
4.33x
POCF Ratio
32.81
PFCF Ratio
32.81
Price to Book Ratio
3.3
EV to Sales
4.5
EV Over EBITDA
16.95
EV to Operating CashFlow
34.12
EV to FreeCashFlow
34.12
Earnings Yield
0.02
FreeCashFlow Yield
0.03
Market Cap
26,71 Bil.
Enterprise Value
27,77 Bil.
Graham Number
324.12
Graham NetNet
11.09

Income Statement Metrics

Net Income per Share
18.62
Income Quality
1.35
ROE
0.08
Return On Assets
0.05
Return On Capital Employed
0.09
Net Income per EBT
0.79
EBT Per Ebit
0.97
Ebit per Revenue
0.13
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.58
Operating Profit Margin
0.13
Pretax Profit Margin
0.12
Net Profit Margin
0.1

Dividends

Dividend Yield
0
Dividend Yield %
0.3
Payout Ratio
0
Dividend Per Share
2.5

Operating Metrics

Operating Cashflow per Share
25.21
Free CashFlow per Share
25.21
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.07
Return on Tangible Assets
0.05
Days Sales Outstanding
104.25
Days Payables Outstanding
115.38
Days of Inventory on Hand
50.19
Receivables Turnover
3.5
Payables Turnover
3.16
Inventory Turnover
7.27
Capex per Share
0

Balance Sheet

Cash per Share
76,74
Book Value per Share
250,79
Tangible Book Value per Share
250.04
Shareholders Equity per Share
250.79
Interest Debt per Share
42.4
Debt to Equity
0.15
Debt to Assets
0.11
Net Debt to EBITDA
0.65
Current Ratio
1.5
Tangible Asset Value
8,07 Bil.
Net Current Asset Value
0,59 Bil.
Invested Capital
7967199999
Working Capital
1,40 Bil.
Intangibles to Total Assets
0
Average Receivables
0,88 Bil.
Average Payables
0,41 Bil.
Average Inventory
179035000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Krsnaa Diagnostics Limited Dividends
Year Dividends Growth
2022 3
2023 3 0%
2024 3 0%

Krsnaa Diagnostics Limited Profile

About Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited provides diagnostic services. The company offers a range of technology-enabled diagnostic services, such as radiology, pathology/clinical laboratory, and tele-radiology services to public and private hospitals, medical colleges, and community health centers. As of December 31, 2020, it operated 1,801 diagnostic centers in 13 states across India. The company was incorporated in 2010 and is based in Pune, India.

CEO
Mr. Mitesh Dave
Employee
3.700
Address
S.No.243,A-Hissa No.6/6
Pune, 411019

Krsnaa Diagnostics Limited Executives & BODs

Krsnaa Diagnostics Limited Executives & BODs
# Name Age
1 Mr. Gaurav Sachdev
National Sales Head
70
2 Mr. Mitesh Dave
Group Chief Executive Officer
70
3 Dharmendra Kumar Madan Lal Sharma
Vice President
70
4 Mr. Sujoy Sudipta Bose
Company Secretary & Compliance Officer
70
5 Mr. Yash Prithviraj Mutha C.A.
Joint MD, Manager & Whole-Time Director
70
6 Mr. Rajendra Khivraj Mutha
Executive Chairman
70
7 Mr. Pawan Daga C.A.
Chief Financial Officer
70

Krsnaa Diagnostics Limited Competitors